Status:
RECRUITING
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
Stanford University
National Institute of Nursing Research (NINR)
Conditions:
Mild Cognitive Impairment
Healthy Aging
Eligibility:
All Genders
60-89 years
Phase:
PHASE2
Brief Summary
A recently completed study suggested that processing speed and attention (PS/A) oriented cognitive training (VSOP) produced robust effect on PS/A and working memory, but not in cognitive control or ep...
Eligibility Criteria
Inclusion
- All participants will require a diagnosis of "mild cognitive impairment due to Alzheimer's disease"using the most recent NIA and Alzheimer's Association workshop criteria:
- Presence of memory complaint,
- Rey Auditory Verbal Learning Test delayed recall (for memory) \< 6,
- Montreal Cognitive Assessment (for global cognition) ranged 18 and 25,
- Activities of Daily Living Questionnaire ≤ 30,
- Intact score for San Diego Brief Assessment of Capacity to Consent (UBACC).
- If a participant is on Alzheimer's disease medication (i.e., memantine or cholinesterase inhibitors), antidepressants, anxiolytics, or vascular risk or diseases related medications (e.g., beta- blocker), the dose should be stable for 3 months prior to recruitment.
- Age 60-89,
- English-speaking,
- Adequate visual and hearing acuity for using mobile-based apps and testing by self-report, and
- Community-dwelling.
Exclusion
- Current enrollment in another cognitive improvement study;
- Uncontrollable symptoms of major depression;
- Major cerebrovascular and cardiovascular diseases (e.g., congestive heart failure, pacemaker, prior myocardial infarction);
- Neurological diseases (e.g., Parkinson's disease, Multiple Sclerosis);
- Having an active legal guardian (indicating impaired capacity for decision making);
- MRI contraindication (e.g., pacemaker, claustrophobia).
- Color blindedness
- Alcohol dependency in the past 5 years that are the main contributor to MCI
Key Trial Info
Start Date :
August 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04522791
Start Date
August 18 2020
End Date
February 28 2026
Last Update
July 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Feng Lin
Rochester, New York, United States, 14642-0001